{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:14:40Z","timestamp":1774908880140,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","award":["MGH Ralph Schlaeger Research Fellow Award"],"award-info":[{"award-number":["MGH Ralph Schlaeger Research Fellow Award"]}],"id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA241365"],"award-info":[{"award-number":["K08CA241365"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10549-023-07036-5","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T23:02:45Z","timestamp":1690758165000},"page":"185-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram"],"prefix":"10.1007","volume":"202","author":[{"given":"Kimberlee A.","family":"Hashiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-7690","authenticated-orcid":false,"given":"Manisha","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"key":"7036_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jbi\/wbz039","volume":"1","author":"M Shehata","year":"2019","unstructured":"Shehata M, Grimm L, Ballantyne N, Lourenco A, Demello LR, Kilgore MR, Rahbar H (2019) Ductal carcinoma in situ: current concepts in biology, imaging, and treatment. J Breast Imaging 1:166\u2013176. https:\/\/doi.org\/10.1093\/jbi\/wbz039","journal-title":"J Breast Imaging"},{"key":"7036_CR2","unstructured":"American Cancer Society (2023) Cancer Facts & Figures 2023. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf. Accessed 30 January 2023"},{"key":"7036_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R (2022) Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030","journal-title":"J Natl Compr Canc Netw"},{"key":"7036_CR4","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","volume":"28","author":"U Rudloff","year":"2010","unstructured":"Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 28:3762\u20133769. https:\/\/doi.org\/10.1200\/JCO.2009.26.8847","journal-title":"J Clin Oncol"},{"key":"7036_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jncimonographs\/lgq040","volume":"2010","author":"MJ Silverstein","year":"2010","unstructured":"Silverstein MJ, Lagios MD (2010) Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California\/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr 2010:193\u2013196. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq040","journal-title":"J Natl Cancer Inst Monogr"},{"key":"7036_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bjs.4051","volume":"90","author":"GP Boland","year":"2003","unstructured":"Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ (2003) Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 90:426\u2013432. https:\/\/doi.org\/10.1002\/bjs.4051","journal-title":"Br J Surg"},{"key":"7036_CR7","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.23089","volume":"110","author":"SG MacAusland","year":"2007","unstructured":"MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, Wazer DE (2007) An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110:2648\u20132653. https:\/\/doi.org\/10.1002\/cncr.23089","journal-title":"Cancer"},{"key":"7036_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.2011.36.4976","volume":"30","author":"M Yi","year":"2012","unstructured":"Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK (2012) Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30:600\u2013607. https:\/\/doi.org\/10.1200\/JCO.2011.36.4976","journal-title":"J Clin Oncol"},{"key":"7036_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","volume":"21","author":"LJ Solin","year":"2019","unstructured":"Solin LJ (2019) Management of ductal carcinoma in situ (DCIS) of the breast: present approaches and future directions. Curr Oncol Rep 21:33. https:\/\/doi.org\/10.1007\/s11912-019-0777-3","journal-title":"Curr Oncol Rep"},{"key":"7036_CR10","doi-asserted-by":"publisher","first-page":"22645","DOI":"10.1038\/s41598-021-02126-0","volume":"11","author":"M Kunkiel","year":"2021","unstructured":"Kunkiel M, Niwinska A (2021) Assessment of the usefulness of prognostic Van Nuys Prognostic Index in the treatment in ductal carcinoma in situ in 15-year observation. Sci Rep 11:22645. https:\/\/doi.org\/10.1038\/s41598-021-02126-0","journal-title":"Sci Rep"},{"key":"7036_CR11","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/j.adro.2020.10.020","volume":"6","author":"RY Lei","year":"2021","unstructured":"Lei RY, Carter DL, Antell AG, Nowels MA, Tole SP, Bennett JP, Turner M, Baehner FL, Leonard CE (2021) A comparison of predicted ipsilateral tumor recurrence risks in patients with ductal carcinoma in situ of the breast after breast-conserving surgery by breast radiation oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS score assay. Adv Radiat Oncol 6:100607. https:\/\/doi.org\/10.1016\/j.adro.2020.10.020","journal-title":"Adv Radiat Oncol"},{"key":"7036_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clinimag.2022.08.023","volume":"92","author":"LR Lamb","year":"2022","unstructured":"Lamb LR, Mercaldo S, Kim G, Hovis K, Oseni TO, Bahl M (2022) Predicting ipsilateral recurrence in women treated for ductal carcinoma in situ using machine learning and multivariable logistic regression models. Clin Imaging 92:94\u2013100. https:\/\/doi.org\/10.1016\/j.clinimag.2022.08.023","journal-title":"Clin Imaging"},{"key":"7036_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clinimag.2021.11.018","volume":"82","author":"K Hovis","year":"2022","unstructured":"Hovis K, Mercaldo S, Kim G, Lamb LR, Oseni TO, Bahl M (2022) Contralateral breast cancer after curative-intent treatment for ductal carcinoma in situ: rate and associated clinicopathological and imaging risk factors. Clin Imaging 82:179\u2013192. https:\/\/doi.org\/10.1016\/j.clinimag.2021.11.018","journal-title":"Clin Imaging"},{"key":"7036_CR14","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1007\/s00330-020-07021-2","volume":"30","author":"G Kim","year":"2020","unstructured":"Kim G, Mikhael PG, Oseni TO, Bahl M (2020) Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade. Eur Radiol 30:6089\u20136098. https:\/\/doi.org\/10.1007\/s00330-020-07021-2","journal-title":"Eur Radiol"},{"key":"7036_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.acra.2019.09.025","volume":"27","author":"LR Lamb","year":"2020","unstructured":"Lamb LR, Lehman CD, Oseni TO, Bahl M (2020) Ductal carcinoma in situ (DCIS) at breast MRI: predictors of upgrade to invasive carcinoma. Acad Radiol 27:1394\u20131399. https:\/\/doi.org\/10.1016\/j.acra.2019.09.025","journal-title":"Acad Radiol"},{"key":"7036_CR16","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1245\/s10434-020-08576-6","volume":"27","author":"TO Oseni","year":"2020","unstructured":"Oseni TO, Smith BL, Lehman CD, Vijapura CA, Pinnamaneni N, Bahl M (2020) Do eligibility criteria for ductal carcinoma in situ (DCIS) active surveillance trials identify patients at low risk for upgrade to invasive carcinoma? Ann Surg Oncol 27:4459\u20134465. https:\/\/doi.org\/10.1245\/s10434-020-08576-6","journal-title":"Ann Surg Oncol"},{"key":"7036_CR17","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.acra.2020.02.011","volume":"28","author":"LR Lamb","year":"2021","unstructured":"Lamb LR, Kim G, Oseni TO, Bahl M (2021) Noncalcified ductal carcinoma in situ (DCIS): rate and predictors of upgrade to invasive carcinoma. Acad Radiol 28:e71\u2013e76. https:\/\/doi.org\/10.1016\/j.acra.2020.02.011","journal-title":"Acad Radiol"},{"key":"7036_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clinimag.2020.11.050","volume":"73","author":"SL Venkatesh","year":"2021","unstructured":"Venkatesh SL, Oseni TO, Bahl M (2021) Symptomatic ductal carcinoma in situ (DCIS): upstaging risk and predictors. Clin Imaging 73:101\u2013107. https:\/\/doi.org\/10.1016\/j.clinimag.2020.11.050","journal-title":"Clin Imaging"},{"key":"7036_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1245\/s10434-020-09101-5","volume":"28","author":"LR Lamb","year":"2021","unstructured":"Lamb LR, Mercaldo S, Oseni TO, Bahl M (2021) Predictors of reexcision following breast-conserving surgery for ductal carcinoma in situ. Ann Surg Oncol 28:1390\u20131397. https:\/\/doi.org\/10.1245\/s10434-020-09101-5","journal-title":"Ann Surg Oncol"},{"key":"7036_CR20","doi-asserted-by":"publisher","first-page":"109130","DOI":"10.1016\/j.ejrad.2020.109130","volume":"129","author":"LR Lamb","year":"2020","unstructured":"Lamb LR, Oseni TO, Lehman CD, Bahl M (2020) Pre-operative MRI in patients with ductal carcinoma in situ: is MRI useful for identifying additional disease? Eur J Radiol 129:109130. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109130","journal-title":"Eur J Radiol"},{"key":"7036_CR21","unstructured":"Memorial Sloan Kettering Cancer Center (2014) Breast Cancer Nomogram. http:\/\/nomograms.mskcc.org\/breast\/DuctalCarcinomaInSituRecurrencePage.aspx. Accessed 15 December 2021"},{"key":"7036_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jnci\/djh260","volume":"96","author":"LA Habel","year":"2004","unstructured":"Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB (2004) Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 96:1467\u20131472. https:\/\/doi.org\/10.1093\/jnci\/djh260","journal-title":"J Natl Cancer Inst"},{"key":"7036_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejso.2003.11.004","volume":"30","author":"S Roka","year":"2004","unstructured":"Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 30:243\u2013247. https:\/\/doi.org\/10.1016\/j.ejso.2003.11.004","journal-title":"Eur J Surg Oncol"},{"key":"7036_CR24","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1002\/cncr.24638","volume":"115","author":"T Cil","year":"2009","unstructured":"Cil T, Fishell E, Hanna W, Sun P, Rawlinson E, Narod SA, McCready DR (2009) Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 115:5780\u20135787. https:\/\/doi.org\/10.1002\/cncr.24638","journal-title":"Cancer"},{"key":"7036_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-011-1387-4","volume":"127","author":"SY Wang","year":"2011","unstructured":"Wang SY, Shamliyan T, Virnig BA, Kane R (2011) Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 127:1\u201314. https:\/\/doi.org\/10.1007\/s10549-011-1387-4","journal-title":"Breast Cancer Res Treat"},{"key":"7036_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.mcna.2017.03.005","volume":"101","author":"CI Lee","year":"2017","unstructured":"Lee CI, Chen LE, Elmore JG (2017) Risk-based breast cancer screening: implications of breast density. Med Clin North Am 101:725\u2013741. https:\/\/doi.org\/10.1016\/j.mcna.2017.03.005","journal-title":"Med Clin North Am"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:12:19Z","timestamp":1694754739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["7036"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07036-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}},{"value":"Financial interests: Dr. Hashiba has no financial interests. Dr. Bahl is an expert panelist for 2nd.MD. She has previously served as a consultant for Lunit and as an advisory board member for Hologic. Non-financial interests: The authors have no relevant non-financial interest to disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective study was approved by the Massachusetts General Hospital Institutional Review Board and compliant with the Health Insurance Portability and Accountability Act.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This retrospective study was exempted from the written informed consent requirement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The abstract was presented at the American Roentgen Ray Society (ARRS) Annual Meeting in New Orleans, LA, in May 2022. Dr. Hashiba received the ARRS Executive Council Award.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentations"}},{"value":"Dr. Hashiba has no disclosures. Dr. Bahl is an expert panelist for 2nd.MD. She has served as a consultant for Lunit and as an advisory board member for Hologic. These relationships are not directly relevant to the submitted work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Disclosures"}}]}}